Skip to content

Cross-cultural Adaptation to the Spanish Population and Validation of the BESTest and Mini-BESTest

Cross-cultural Adaptation to the Spanish Population and Validation of the Test of Systems of Evaluation of Balance (BESTest) and Its Version Reduced in Persons With Acquired Brain Injury in Subacute and Chronic Phase

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04052087
Acronym
BESTest
Enrollment
104
Registered
2019-08-09
Start date
2021-03-15
Completion date
2022-06-30
Last updated
2022-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Damage

Keywords

Brain Damage Acquired, BDA in subacute and chronic stage, BESTest, Mini-BESTest, Balance, Postural control, Brain Stroke, Stroke, Cross-cultural adaptation

Brief summary

Due to brain damage acquired (BDA), is often difficulty in gait and balance alterations, as problems that patients designated as the most disabling. It is essential to an effective assessment of the balance. Objective: The purpose of the present project adapt and verify the validity of the scale MiniBESTest, version of the BESTest, in patients with BDA in subacute and chronic stage, since that is postulated as a brief tool and covering the peculiarities of the specific alterations of the patient after suffering brain damage. Methodology: Between September 2019 and December 2020 will be transcultural adaptation to the BDA and validation of psychometric scale Mini-BESTest in three phases. 60 subjects who receive treatment in the center of attention State reference to brain damage (CEADAC), together with the comunidad de Madrid private neurological rehabilitation centers will be recruited. Results: validity and reliability parameters shall be calculated by means of descriptive statistics for each item of the scales and the set of scale score. You will also analyze the internal consistency using Cronbach's alpha, the interclass correlation coefficient will be used to determine the reliability, and the items will be scanned with the Pearson coefficient: \> 0.20, among other parameters.

Detailed description

Marta Fernández Hontoria, physiotherapist at the State Reference Center of Attention to Brain Injury (CEADAC), will develop, together with her team formed by Cristina Lirio Romero and María Torres Lacomba of the Department of Physiotherapy at the University of Alcalá, a cross-cultural adaptation to the Spanish population with Adquired Brain Injury (ABI) and psychometric validation of the Mini-BESTest scale. Previously, the author of the scale has been asked for consent. The study will take place at the CEADAC. After receiving the approval of the Ethics and Clinical Research Committee of the University of Alcalá (Madrid), it is proposed to implement the study between September 2019 and May 2020. A minimum of 100 adults, aged between 18 and 65, will be recruited subacute or chronic state after suffering brain damage. The sample size conforms to COSMIN recommendations. After verifying that there are no parallel studies on the subject in progress, the possible participants will be informed of the development of the investigation (ANNEX 1), who must sign the informed consent (ANNEX 2) before being recruited into the study. In addition, a coding sheet (ANNEX 3) of the participants will be filled in so that from now on the data related to the proper name does not appear but with a number that ensures the protection of their data. The participants will be all users of CEADAC and the selection criteria to enter to participate in the study will be: adults who had suffered a ABI at least 2 months ago, that their disability before suffering it was less than or equal to three on the scale modified by Rankin, who have an absence of cognitive impairment according to the Minimental State Examination scale, that is, a score in it greater than 24, without previous diseases that alter the balance, that were clinically stable and without fever, with the ability to walk with help technical or without it, and that they gave their informed consent. On the other hand, those people with medical contraindications for physical tests (acute musculoskeletal or peripheral nervous system disorders), who did not understand the instructions, severe aphasias or with subjects with acute processes of any added pathology will be excluded. The study was developed in 3 phases: Phase 1: Transcultural adaptation process. Phase 2: Pre-Test: collected , as well as the ease of interpretation of the results. Phase 3: Psychometric validation process.

Interventions

None listed

Sponsors

University of Castilla-La Mancha
CollaboratorOTHER
University of Alcala
CollaboratorOTHER
Centro de Referencia Estatal de Atención Al Daño Cerebral
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
16 Years to 54 Years
Healthy volunteers
No

Inclusion criteria

* The participants will be all Ceadac's users. * Adults who had suffered a BDA, at least 2 months before. * The disability before suffering BDA was less than or equal to three on the scale modified Rankin. * Lack of cognitive impairment scale Minimental State Examination, with a score is \> 24. * No previous diseases that alter the balance. * Clinically stable and without fever- * Ability to walk with technical support or without it. * Signing an informed consent.

Exclusion criteria

* Medical contraindications to perform physical tests (acute or peripheral nervous system musculoskeletal disorders). * Not understand the instructions. * Subjects with severe aphasia. * Subjects with acute processes of any added pathology.

Design outcomes

Primary

MeasureTime frameDescription
Test-retest Reliability2 monthsthe overall consistency measures the homogeneity of the scale and the interdependence of the items, indicating the relationship between them. To determine test-retest test reliability, the intraclass correlation coefficient (ICC) will be used. Derived from the test-retest reliability study, the measurement error will be calculated, using the formula ED (estandar deviation) x √1-ICC.
Validity2 monthsTo analyze the convergent validity, it will be applied on the first day of the week and before receiving treatment. Along with the scales to be evaluated, other balance scales will be administered.

Secondary

MeasureTime frameDescription
Sensitivity to change2 monthsAbility of the instrument to detect real changes in the health of the subjects, whether positive or negative. The differences in the scores between the periods of the beginning of any proposed treatment and at the end of this will be evaluated by the effect size and the standardized response to the change.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026